Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

This article was originally published in The Pink Sheet Daily

Executive Summary

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

You may also be interested in...



News In Brief

Transcatheter valve registry launched. Qiagen cuts costs. FCC grants RF spectrum for Medical Micropower Networks. More industry news.

CDRH’s Mansfield Addresses Upcoming Drug/Dx Co-Development Guidance

Either an IND or an IDE will be sufficient for companion diagnostic studies, a CDRH diagnostics official clarified last week. That is among the issues that will be addressed in an upcoming co-development draft guidance.

FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail

FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel